, indicating a different genetic architecture underlying FTD and ALS in these populations. The age of onset of C9FTD/ALS ranges from 27 to 83 years of age, and the disease duration ranges from 1 to 22 years 3, 4 . C9orf72 repeat expansions have also been identified as a rare cause of other neurodegenerative diseases 4 , including Parkinson disease, progressive supranuclear palsy, ataxia, corticobasal syndrome, Huntington disease-like syndrome, Creutzfeldt-Jakob disease and Alzheimer disease.
The vast majority (>95%) of neurologically healthy individuals have ≤11 hexanucleotide repeats in the C9orf72 gene [5] [6] [7] . The pathological repeat length threshold has not been clearly defined; an arbitrary cut-off of 30 repeats is used in most studies, but larger expansions ranging from hundreds to thousands of repeats are most commonly observed in patients with C9FTD/ ALS 6, [8] [9] [10] . Importantly, the discovery of C9FTD/ALS has heightened the realization that ALS and FTD are intimately linked on a clinical, genetic, pathological and mechanistic spectrum.
The expanded GGGGCC repeats are bidirectionally transcribed into repetitive RNA, which forms sense and antisense RNA foci [11] [12] [13] [14] [15] . Remarkably, despite being within a non-coding region of C9orf72, these repetitive RNAs can be translated in every reading frame to form five different dipeptide repeat proteins (DPRs) -poly-GA, poly-GP, poly-GR, poly-PA and poly-PR -via a non-canonical mechanism known as repeat-associated non-ATg (RAN) translation [14] [15] [16] [17] [18] (Fig. 2) .
Although C9orf72 mutations are a relatively recent discovery, progress in understanding their pathogenic effects has been rapid. Three competing but nonexclusive mechanisms have arisen: loss of function of the C9orf72 protein, toxic gain of function from sense and antisense C9orf72 repeat RNA or toxic gain of function from DPRs. These mechanisms are all likely to contribute to disease to some extent, but it is crucial to determine their relative importance at various disease stages to inform therapeutic strategies. The differential involvement of these mechanisms might also explain the clinical, pathological and prognostic heterogeneity that is observed in patients with C9FTD/ALS.
In this article, we review the current understanding of the mechanisms underlying C9FTD/ALS, and the questions that remain unanswered. The clinical and genetic aspects of C9FTD/ALS have been extensively reviewed elsewhere 19, 20 and are not discussed in detail here.
Repeat-associated non-ATG (RAN) translation
Translation is canonically dependent on an ATg start codon for initiation. RAN translation is a non-canonical form of translation that, in the presence of repetitive sequences, can start without the need for an ATg codon.
Repeat size and somatic mosaicism
Defining the minimum number of hexanucleotide repeats in C9orf72 that cause disease would be invalu able for genetic counselling and to guide disease modelling, but this issue is currently unresolved. Neurologically healthy individuals and patients with ALS or FTD can all have 20-30 repeats, so whether repeat lengths within this range can drive disease is unclear. For example, a screen of control post-mortem brains identified an individual with 30 repeats, sparse RNA foci and DPR inclusions but no neurological symptoms up until death at 84 years of age 21 . One confounding factor for accurate repeat sizing is somatic instability of the mutation. Individuals have been identified with large expansions within the CNS but an intermediate repeat length in DNA extracted from blood [22] [23] [24] . These studies show that >50 repeats in blood-derived DNA can be associated with large CNS expansions, suggesting that 50 repeats is a useful cut-off when analysing blood DNA. However, the current data do not support a single precise cut-off; for instance, 70 repeats were insufficient to cause disease in an 89-year-old whose children inherited much larger expansions and went on to develop C9FTD/ALS 25 . Furthermore, defining a cut-off for blood-derived DNA does not help answer the key question of the minimum repeat size required in the CNS to cause disease.
A further confounder is that repeat size varies between different brain regions 8, 10 . This so-called somatic mosaicism within the CNS might explain some of the clinical heterogeneity that is observed between patients, but is currently not well understood.
Pathological features of C9FTD/ALS TDP-43 inclusions
The overwhelming majority of ALS cases and approximately 50% of FTD cases are characterized by inclusions consisting of the RNA-binding protein TDP-43 (TAR DNA-binding protein 43) in neurons and glia 26, 27 . The fact that C9orf72 mutations can lead to TDP-43 inclusions (Fig. 3) in both ALS and FTD implies a final common pathway in these diseases 28 . This pathology is evident in various brain regions, including the frontal, temporal and primary motor cortices, hippocampus, basal ganglia, amygdala, thalamus and midbrain [29] [30] [31] [32] [33] . Patients with C9orf72 mutations who have a predominant ALS syndrome can still exhibit extramotor pathological features consistent with FTD, and conversely, those with a predominant FTD syndrome can show pathology in the motor system 31 .
RNA foci
Sense and antisense RNA foci comprising C9orf72 repeat RNA are widely distributed across the CNS in patients with C9FTD/ALS (Fig. 3) . These foci are found predominantly within neuronal nuclei in the frontal and motor cortices, hippocampus, cerebellum and spinal cord (in motor neurons and occasionally in interneurons) and sporadically in the cytoplasm 11, [13] [14] [15] 34 . Less frequently, foci are detected in astrocytes, microglia and oligodendrocytes 11, 13, 15 . Sense RNA foci occur in ~37% and antisense foci occur in ~26% of neurons in the frontal cortex 11, 34 , and they co-occur in ~14% of frontal cortex neurons 11 . DPR pathology DPR inclusions are positive for ubiquitin-binding protein p62 (also known as sequestosome 1) and negative for TDP-43 and can consist of more than one DPR 18 ( Fig. 3) . Several studies have examined DPRs in patients with C9orf72 repeat expansions, using immunohistochemistry [14] [15] [16] [17] [18] 29, [35] [36] [37] [38] [39] [40] [41] [42] , immunoblotting 14, 16, 17, 38, 41 or immunoassays 43 , and have reached similar conclusions. DPRs most commonly form neuronal cytoplasmic inclusions [15] [16] [17] 29 but can also exist as neuritic inclusions 29, 44 or as pre-inclusions 15, 29 , which appear as diffuse cytoplasmic staining. Neuronal intranuclear inclusions are sometimes observed [15] [16] [17] 29 and are occasionally paranucleolar 36 . Sense-derived poly-GA is the most frequent form of DPR 16, 18, [38] [39] [40] [41] , followed by poly-GP then poly-GR. The antisense-derived DPRs poly-PA and poly-PR are the least frequent forms 15, 18, 35, 36, [38] [39] [40] . Although sense-derived DPRs seem to be more prevalent than antisense-derived DPRs in patients with C9orf72 repeat expansions, both sense-derived and antisense-derived poly-GP are detected in hippocampal neurons in these individuals, with strand-specific antibodies suggesting a preponderance of antisense-derived poly-GP 14 . Staining of cortical tissue with antibodies specific to the carboxyterminal region of the translated DPRs revealed that translation occurs beyond the 3´ end of the repeats in C9orf72 repeat expansion carriers 14, 18 . DPR pathology is most prominent in the cerebellum, hippocampus and neocortex, is less frequent in subcortical regions and is rarely observed in the brainstem and spinal cord. In addition, all DPRs can be detected in insoluble fractions from patient frontal cortex or cerebellum as high-molecular-mass species, indicating that they are prone to aggregation 14, 16, 17, 38 . A Meso Scale Discovery immunoassay has quantitatively detected poly-GP and poly-GA -but not, to date, any of the other DPRs -in both CNS tissue 43 and cerebrospinal fluid (CSF) 45 . CSF poly-GP levels might have utility as a biomarker for both diagnosis and pharmacodynamic response [46] [47] [48] .
Pathogenesis of C9FTD/ALS
The complementary use of human tissue and in vitro and in vivo models, including illuminating mouse models examining both loss-of-function and gain-of-function mechanisms, has informed our current understanding of the contribution of C9orf72 loss of function, C9orf72
Key points
• Rapid progress has been made in the understanding of how repeat expansions in C9orf72 cause C9orf72-associated frontotemporal dementia and/or amyotrophic lateral sclerosis (C9FTD/AlS).
• Both loss of function of C9orf72 and gain of toxic function of the repeats are implicated in C9FTD/AlS. • A range of new models, including mice, Drosophila and patient neurons, have provided new insights into the disease mechanisms.
• Several cellular pathways are affected in C9FTD/AlS and could provide new options for treatment.
• Targeted therapeutic strategies against the repeats themselves are the most advanced and are progressing towards clinical trials.
repeat RNA and DPRs to pathogenesis. These studies have also implicated several downstream mechanisms resulting from C9orf72 expansions (Fig. 4) .
Loss-of-function mechanisms
C9orf72 transcription and splicing. In C9orf72 transcript variant 2, the repeats are located within the promoter region ( Fig. 1) and thus are not incorporated into variant 2 pre-mRNA but have the potential to affect the expression of this variant. By contrast, in variants 1 and 3, the repeats are within intron 1 and are therefore included in the respective pre-mRNAs. Variant 2 is expressed at higher levels than variants 1 and 3 in CNS tissue 49, 50 . Studies have demonstrated reduced levels of one or more of the C9orf72 transcript variants in blood lymphocytes 1, 51, 52 , induced pluripotent stem cell (iPSC)-derived neurons 12, 49, 53, 54 , frontal cortex 1, 51, [55] [56] [57] [58] [59] , cerebellum 12, 16, [57] [58] [59] , motor cortex 12 and cervical spinal cord 12 from C9orf72 expansion carriers compared with controls. The findings are particularly robust for variants 1 and 2 (ReF.
59
). C9orf72 protein levels might be correspondingly reduced in the frontal cortex 58, 60 . Transcripts upstream of the repeat are increased relative to downstream transcripts in blood lymphocytes and brain and spinal cord tissue from C9orf72 expansion carriers, possibly owing to abortive transcription in the presence of the repeat expansion 61 . Raised levels of variant 1 in the frontal cortex and cerebellum are associated with increased survival 59 -an important consideration when developing therapies that affect transcript levels.
The intronic location of the repeats in variants 1 and 3 means that they should be spliced out of the transcript, but the fact that they are translated into DPRs implies either that they are retained in the transcript or that the spliced intron is translated. Although levels of mature spliced C9orf72 mRNA are reduced in the brains of individuals with C9FTD/ALS, levels of sense and antisense transcripts containing intron 1, where the repeats are located, are increased 14, 16 , suggesting stabilization of repeat RNAs. Mature C9orf72 transcripts with correct splicing or retention of intron 1 are both detected in C9FTD/ALS lymphoblasts and brain tissue 49, 62 , indicating that both species could contribute to RAN translation. The expression of C9orf72 is also modified by epigenetic effects (Box 1).
Autophagy and lysosomal function. Bioinformatic analysis shows that C9orf72 is structurally related to the DENN (differentially expressed in normal and neoplastic cells) guanine nucleotide exchange factor (GEF) proteins, which activate Rab proteins 63, 64 . Rab proteins are crucial for a wide range of vesicular trafficking events, and multiple lines of evidence from several independent groups point to a role for C9orf72 in autophagy and endolysosomal trafficking and function.
Knockdown of C9orf72 in human cell lines and primary neurons inhibits autophagy induction 65, 66 , leading to accumulation of p62 (ReFs 65, 66 ) and cytoplasmic aggregation of TDP-43 (ReF.
66
). Consistent with these findings, accumulation of autophagy substrates, including p62, is observed in the spleens of C9orf72-knockout mice 67, 68 . Conversely, overexpression of C9orf72 can activate autophagy, leading to an increase in autophagosomes in cell lines 65 . The role in autophagy seems to be mediated by the long C9orf72 protein isoform (C9orf72-L) rather than the short isoform (C9orf72-S) 66 . The mechanism underlying these changes involves Rab proteins, although no consensus has been reached on which are the most important, with Rab1a, Rab8a and Rab39b all being implicated 65, 66, [68] [69] [70] . C9orf72 interacts with guanine nucleotide exchange protein SMCR8 and WD repeatcontaining protein 41 (WDR41) 66, 68, [70] [71] [72] [73] , and the effect on autophagy is generally agreed to be mediated through an interaction with the serine/threonine-protein kinase ULK1 complex 65, 66, 68, 70, 74 , a key initiator of autophagy. Potentially, this interaction can also occur via TBK1 (ReF. 66 ), another serine/threonine-protein kinase implicated in autophagy. This finding is particularly intriguing, as loss-of-function mutations in TBK1 cause ALS and FTD 75 . Another link to known ALS-associated genes is through ataxin 2 (ATXN2), in which intermediate expansions of polyglutamine increase the risk of ALS 76 . C9orf72 knockdown specifically increases the aggregation and toxicity of ataxin 2 protein with intermediate polyglutamine repeats 66 . The relevance of the role of C9orf72 in autophagy for disease pathogenesis is unclear, but neurons from patients with C9FTD/ALS have impaired basal autophagy 65, 77 and increased sensitivity to autophagy inhibition 53 , suggesting that reductions in C9orf72 levels contribute to cellular distress. Furthermore, an www.nature.com/nrneurol SRC-ABL pathway inhibitor, which increases autophagic processes, rescues survival defects in neurons derived from patients with ALS 78 . In addition to effects on autophagy, reduced endocytosis was reported in C9orf72 knockdown cell lines 69 , and impaired endosomal and lysosomal trafficking were observed in bone-marrow-derived macrophages and microglia from homozygous C9orf72 knockout mice 67 , as well as in patient-derived fibroblasts and neurons 77 . Moreover, C9orf72 has been shown to reside on lysosomes and can directly affect lysosomal function, which might also explain the effects of C9orf72 loss of function on both endolysosomal trafficking and autophagy 72 . In iPSC-derived motor neurons, C9orf72 primarily localizes to early endosomes, and iPSC-derived motor neurons from patients with C9FTD/ALS have fewer lysosomes than those from healthy controls 54 . Both patient neurons and CRISPR-Cas9 C9orf72-knockout iPSC-derived neurons have reduced vesicular trafficking, which can be rescued by C9orf72 overexpression 54 . These cells also have elevated glutamate receptor levels and increased sensitivity to excitotoxicity 54, 79 . Consistent with this observation, increased glutamate receptor levels were found in spinal cord tissue of C9orf72-knockout mice 54 and in spinal cord 54, 79 and cortical tissue 54 from patients with C9FTD/ALS.
Taken together, these data suggest that C9orf72 is involved in multiple cellular trafficking events, and that loss of C9orf72 in both microglia and neurons can sensitize cells to other insults, thereby contributing to neurodegeneration in C9FTD/ALS.
Further insights from loss-of-function mouse models. The mouse C9orf72 orthologue shares 98% homology with human C9orf72 and is expressed in embryonic and early postnatal neurons, in various regions of the adult brain and in spinal cord, glia, and non-neuronal tissues, including muscle, spleen, kidney and testes 67, [80] [81] [82] [83] [84] . Several C9orf72 knockout or knockdown models have now been reported 67, 68, 71, [81] [82] [83] 85, 86 (TABle 1) .
Transient reduction of C9orf72 expression in the CNS by antisense oligonucleotides (ASOs) 13 and conditional homozygous knockouts of C9orf72 in neurons and glia 81 do not lead to motor or behavioural phenotypes. By contrast, ubiquitous knockouts of C9orf72 (ReFs 67, 71, 82, 83, 85, 86 ) or CRISPR-Cas9-mediated knockouts of C9orf72 isoforms 68, 86 throughout development led to immune system dysregulation in homozygous mice. The phenotypes included changes in myeloid and/or lymphoid cell populations in the spleen and lymph nodes, increased levels of inflammatory cytokines, and cervical or systemic lymphadenopathy and splenomegaly, sometimes with reduced body weight 82, 83, 85, 86 , neoplasia 85 or increased autoimmune antibody titres 83, 86 . In comparison, haploinsufficiency of C9orf72 does not lead to severe phenotypes 67, 83, 86 . Although some studies reported mild motor or cognitive phenotypes 82, 83 or reduced lifespan 71, 82, 83, 85, 86 in homozygous C9orf72-knockout mice, none reported neuronal loss. Transcriptomic analysis confirmed changes in immune pathways 67, 83 , similar to those observed in CNS tissue from patients with C9orf72 repeat expansions 67 . Transcriptomic analysis in human tissue has shown that C9orf72 transcripts are particularly prevalent in CD14 + myeloid cells, which are involved in innate and adaptive immunity 50 . Overall, in line with cellular studies of C9orf72, these findings suggest an important role for C9orf72 in immune regulation, possibly through its effects on autophagosome and lysosome function and/or microglial activity or through alteration of autoimmune responses. However, in contrast to C9orf72 loss of function, knockout of other autophagyrelated genes, including ATG7 (ReF.
87
) and ATG5 (ReF.
88
), in neurons in mice leads to neurodegeneration. These findings suggest that C9orf72 is not an essential component of the autophagy pathway that mediates neuronal survival.
Crucially, none of the mouse C9orf72 knockouts recapitulate ALS or FTD, suggesting that C9orf72 loss of function is insufficient to precipitate disease. However, given the role of C9orf72 in pathways previously implicated in FTD and ALS 89 , haploinsufficiency might contribute to the disease process in combination with gain-of-function mechanisms, and an interesting approach will be to breed loss-of-function mouse models with gain-of-function models.
Gain-of-function mechanisms
The question of whether C9orf72 repeat RNA or DPRs produced by RAN translation are the toxic species in aetiopathogenesis is hotly debated in the field. Various approaches, each of which has limitations, have been used to address this issue. Post-mortem studies generally do not capture the earliest pathogenic events. In vitro and in vivo models often do not feature the long repeats that are found in patients, owing to methodological difficulties in cloning GC-rich repeats of this length. Therefore, these models might not fully recapitulate the disease mechanisms. Overexpression models do not necessarily reflect endogenous expression levels in patients. Many models express expanded repeats, but as these repeats can go on to produce both C9orf72 repeat RNA and DPRs, attribution of downstream mechanisms to either entity is challenging. Despite these uncertainties, however, clear mechanistic pathways have emerged (Supplementary Table 1 ). C9orf72 repeat RNA. In vitro, GGGGCC repeat RNA forms secondary structures, including hairpins 45,61 and highly stable g-quadruplexes 45, 61, [90] [91] [92] . Other secondary structures, including DNA-RNA heteroduplexes, RNA duplexes and i-motifs [93] [94] [95] [96] , might arise from the sense and antisense repeat RNA and DNA sequences. In vivo, such secondary structures are likely to mediate the sequestration -and, as a consequence, depletion -of RNA-binding proteins (RBPs) 61, 90 (Box 2), thus providing a clear potential route to RNA toxicity (reviewed extensively elsewhere 93, 97 ).
DPRs: insights from post-mortem studies. The results of post-mortem studies have raised suspicions that DPR inclusions are not the primary culprit in C9FTD/ALS pathogenesis 29, [35] [36] [37] [38] [39] [40] 43, [98] [99] [100] . TDP-43 pathology and neurodegeneration co-occur in affected regions of the CNS in ALS and FTD 29, 35, [37] [38] [39] 43 . By contrast, DPR pathology does not coincide neuroanatomically with TDP-43 patho logy 43 and is generally not found in the same neurons as TDP-43 inclusions 16, 29, 35, 40 . Furthermore, DPR inclusions do not differ in neuroanatomical distribution between FTD and ALS cases 29, 37, 38 and are rare in the spinal cord in C9orf72-associated ALS, whereas TDP-43 pathology is common 14, 17, 18, 29, [36] [37] [38] [39] [40] . DPR inclusions are frequent across several brain regions 17, [35] [36] [37] 39 , including structures that are thought to be minimally affected in ALS and FTD, such as the cerebellum and occipital and parietal lobes. However, one study showed that poly-GR inclusions -but not the other DPRs -correlated with areas of neurodegeneration in C9orf72-associated ALS and were also unique among the DPRs in colocalizing with TDP-43 pathology in a small sample of brains that were obtained shortly after death 44 . These data suggest that further investigation in larger, deep-phenotyped post-mortem cohorts will provide important insights.
Despite these observations, strong counterarguments to support a pathogenic role for DPRs in C9FTD/ALS have been put forward. Post-mortem studies tend to represent the final stages of the disease process and might not reflect the early pathogenicity of DPRs. Aggregates observed at post-mortem could represent protective species, and correlations with inclusions might be misleading if soluble species mediate neurotoxicity. CNS regions that have extensive DPR pathology but are unaffected by neurodegeneration might contain protective factors; indeed, selective vulnerability is a frequent observation in neurodegenerative diseases 101 . TDP-43 pathology is likely to be downstream of DPR pathology, probably explaining why it correlates more closely with neurodegeneration. This idea is consistent with downstream effects on TDP-43 in some experimental models expressing expanded repeats 102, 103 or pure DPRs 104 , suggesting that one or both of these gain-of-function mechanisms are linked to TDP-43. Affected individuals with DPR pathology but relatively mild or absent TDP-43 pathology have been reported 16, 21, 43, 55, 99, 105, 106 . These individuals include a young patient with evidence of intellectual disability 105 , a patient with C9orf72-associated ALS who had little extramotor TDP-43 pathology but showed evidence of cognitive impairment and high cerebellar DPR levels 43 , and patients with pathological or clinical diagnoses of frontotemporal lobar degeneration (FTLD) or FTD 16, 55, 99, 105, 106 , some of whom died prematurely from other causes 99 . Therefore, DPR pathology without substantial TDP-43 pathology seems to be sufficient for disease to develop in some cases. Furthermore, as discussed below, considerable evidence from model systems indicates that DPRs can cause neurodegeneration.
Insights from gain-of-function models
Evidence for C9orf72 repeat RNA toxicity. The effects of C9orf72 repeat RNA were modelled in primary cortical and motor neurons transfected with expanded GGGGCC repeats within an artificial intronic region of the green fluorescent protein gene, reflecting the intronic human genomic context of C9orf72 expansions 42 . These neurons demonstrated nuclear RNA foci and reduced survival. Dot blots and immunocytochemistry revealed no DPRs in these cells, suggesting that the reduced survival was attributable to repeat RNA. Interestingly, however, co-expression of poly-PR and the intronic expanded GGGGCC repeats had a synergistic detrimental effect on neuronal survival. 
G-quadruplexes
secondary structures formed by guanine-rich RNA or DNA molecules consisting of a stack of g-quartets (four guanine residues aligned in a square planar configuration).
i-motifs
Four-stranded secondary structures formed by cytosine-rich DNA or RNA molecules.
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RNA toxicity has also been implicated in eye and motor neuron degeneration in a Drosophila model that expresses 30 GGGGCC repeats with a 6 bp (CTCGAG) interruption in the middle of the repeats 102, 107 . DPRs were not detected in the eyes or neurons and were detected only when the repeats were strongly induced in all tissues 102 . One caveat for the interpretation of both studies is that the inability to detect DPRs is not sufficient to exclude a role for these proteins. In our experience, poly-GR can be difficult to detect even in flies that express this protein at high levels and show overt toxicity. Therefore, more sensitive detection assays for DPRs will be required to unpick the relative contributions of RNA and DPRs in these models.
A study in developing zebrafish found that both sense and antisense RNA repeats could mediate toxicity, leading to a motor axonopathy phenotype 108 . No DPRs were detected in this model. In a Drosophila model, however, neither sense nor antisense repeats with similar lengths to those found in patients with C9FTD/ALS led to degeneration of adult neurons 109 . One potential explanation for this difference is that developing neurons are more susceptible to RNA toxicity than are adult neurons. Another possibility is that RNA foci in humans sequester RBPs that are not present in Drosophila, thereby limiting the utility of Drosophila as a model for RNA toxicity.
Evidence for DPR toxicity. Two studies in Drosophila models have provided evidence that neurotoxicity is attributable to DPRs rather than repeat RNA 49, 110 . In the first study, overexpression of expanded GGGGCC repeats in Drosophila eyes or adult neurons led to neurodegeneration 110 . This effect was inhibited when the repeats were interrupted by stop codons in each reading frame that prevented translation of the repeats into DPRs. The second study involved ubiquitous overexpression of 160 GGGGCC repeats in an intronic context, flanked by human C9orf72 sequence 49 . The intron containing the repeat was spliced out and formed large . C9orf72 loss-of-function and toxic gain-of-function mechanisms can both alter RNA processing and metabolism pathways, with alterations in stress granules and P-bodies, and C9orf72 gain-of-function mechanisms can lead to nucleolar dysfunction, affect RNA splicing and transcription and cause DNA damage. Proteostasis pathways have also been implicated, with impairments in autophagy and lysosomal function, the unfolded protein response, the endoplasmic reticulum and the ubiquitin-proteasome system. Other cellular processes, including nucleocytoplasmic transport, vesicular trafficking and transport granule function, and mitochondrial function, can also be impaired. In addition, neuron-specific processes, including hyperexcitability and hypoexcitability , glutamate excitotoxicity , axonal transport and neuronal branching defects, have been implicated in C9orf72-associated FTD and/or ALS (C9FTD/ALS). Finally , loss of C9orf72 function alters immune system and microglial function.
numbers of sense RNA foci in neurons and glia, without production of DPRs. This model showed no evidence of neurodegeneration, reduced survival or widespread transcriptomic changes. Increasing transgene expression in this model led to DPR production and lifespan reduction, although the frequency of sense foci remained the same 49 , supporting the idea that DPRs rather than sense foci mediate neurodegeneration.
It should be noted that although the RNA sequence interrupted by stop codons that was used in the first study forms the same G-quadruplex secondary structure as uninterrupted C9orf72 repeat RNA 110 , the tertiary and quaternary structures are not necessarily identical, which might affect the dynamics of RBP sequestration. However, the intronic model did not have an interrupted repeat sequence and exhibited multiple sense foci yet still showed no evidence of toxicity 49 .
Toxicity of individual DPRs. In numerous studies in cell models 14, 42, 104, [111] [112] [113] [114] [115] , Drosophila 42, 110, [116] [117] [118] [119] , zebra fish 108, 120, 121 and mice 122, 123 , the repetitive GGGGCC sequence was altered to generate coding sequences that expressed each DPR in isolation, which was often sufficient to produce neurotoxicity and implicate several downstream mecha nisms. The main limitation of these models is that DPR overexpression might not reflect the endogenous mechanisms that are seen in patients.
Studies in cultured neuronal or non-neuronal cell lines or primary neuronal cultures indicate that poly-GR and poly-PR are the most toxic of the DPRs 42, 104, 111, 112, 124 . These arginine-rich DPRs -in particular, poly-PR -are toxic to yeast 125 . Poly-GA and poly-PA are also toxic but to a lesser extent 125 . Synthetic poly-PR and poly-GR are highly toxic when exogenously applied to cultured human astrocytes. Poly-PR has a longer half-life than poly-GR and is especially potent in this context 126 . Synthetic poly-GR and poly-GA are also toxic to primary neurons 127 . Furthermore, overexpression of poly-PR was found to be toxic to wild-type iPSC-derived neurons 42 . Of all the DPRs, poly-GR had the greatest detrimental effect on development, locomotor activity and survival in a zebrafish model 120 . In Drosophila models, poly-GR and poly-PR were neurotoxic when expressed in the eyes 42, 110, [116] [117] [118] [119] . In addition, flies expressing these proteins exhibited reduced survival 42, 110, 117, 119 and locomotor phenotype 42, 119, 128 . Most of these studies found that poly-GA 42, 118, 119 , poly-PA 42, 110 and poly-GP 117 were not toxic in Drosophila, although one study reported a mild reduced survival phenotype when poly-GA was expressed in adult neurons 110 . Consistent with this finding, poly-GA overexpression in cultured cells 113, 114 , primary neurons 113 , zebrafish 120, 121 or mouse brain 122 leads to toxicity, and synthetic poly-GA exogenously applied to human cells 115 or primary neurons 127 is also toxic. In addition, cryo-electron tomography revealed that poly-GA forms twisted ribbon structures that sequester the 26S proteasome 129 .
Overall, these studies show that poly-GR and poly-PR are potently neurotoxic, and that poly-GA also exerts toxicity. The remaining DPRs, poly-PA and poly-GP, are unlikely to be toxic species. As poly-GR, poly-PR and poly-GA can all be damaging when overexpressed, a key aim is to establish the levels of each of these species in patient tissue, particularly at early disease stages. New techniques to extract and measure DPRs from patient tissue and to assess their toxicity will be essential for this endeavour.
Mouse gain-of-function models. Several mouse models of C9orf72 gain of function have been characterized. Adeno-associated virus-mediated CNS overexpression of 66 GGGGCC repeats leads to motor and behavioural phenotypes by 6 months, with RNA foci, DPRs, phospho-TDP-43 inclusions and neuronal loss being observed 130 . The same approach was used to generate mice specifically overexpressing poly-GA in the CNS 122 . These mice developed neuronal cytoplasmic inclusions of fibrillar poly-GA, as well as neurodegeneration and motor, cognitive and behavioural phenotypes. However, these effects were not observed when the poly-GA sequence was mutated to a sequence that was unable to aggregate. Phospho-TDP-43 inclusions were rarely found; therefore, this model does not fully recapitulate the (GGGGCC) 66 repeat mouse phenotype, indicating that species other than poly-GA are the main drivers of phospho-TDP-43 accumulation. A further poly-GA model, with expression levels more comparable to those in the cortex in patients with C9FTD/ALS, demonstrated motor deficits but had a less severe phenotype than the viral poly-GA model overall 123 .
Box 1 | Epigenetic modification of C9orf72
Analysis of blood, frontal cortex and cervical spinal cord DNA from patients with C9orf72-associated frontotemporal dementia and/or amyotrophic lateral sclerosis (C9FTD/AlS) has revealed that in 20-40% of cases, the CpG island in the C9orf72 promoter region upstream of the pathogenic repeats is hypermethylated 22, 52, 176, 177 . This hypermethylation is associated with increased repeat length and reduced transcription of C9orf72. Moreover, analysis of blood DNA from patients with C9FTD/AlS showed that in 97% of cases, the expanded hexanucleotide repeat itself was methylated 177 . A subset of C9orf72 bacterial artificial chromosome transgenic mice also demonstrate hypermethylation of the C9orf72 promoter and increasing hexanucleotide repeat methylation with age 178 . Treatment of C9FTD/AlS patient fibroblasts with a DNA and histone demethylating agent led to an increase in C9orf72 transcript levels 57 . Bromodomain-containing proteins are involved in epigenetic regulation, and bromodomain inhibitors increase C9orf72 expression in cells from patients with C9orf72-associated AlS and control individuals 179 . Histone trimethylation is another epigenetic modification that can reduce gene expression. Chromatin immunoprecipitation experiments in frontal cortex and cerebellar tissue showed that the C9orf72 promoter region is bound to trimethylated histones in C9orf72 repeat expansion carriers 57 . Considerable evidence points to amelioration of disease phenotypes by C9orf72 hypermethylation. Hypermethylation is associated with reductions in RNA foci and dipeptide repeat proteins (DPRs) in patients with C9FTD/AlS 41 and C9orf72 cell models 180 , as well as reduced neuronal and grey matter loss 181 . In addition, hypermethylation has been linked to longer survival in patients with C9orf72-associated FTD 182 and a later age of onset in AlS and FTD 22 . However, hypermethylation also correlates with reduced disease duration before death in patients with C9orf72-associated AlS 52 . one possibility is that some phenotypes are dependent on gain of function and others on loss of function, so hypermethylation could have pleiotropic effects. one might predict that reducing the levels of transcript variants 1 and 3 (Fig. 1) , which are responsible for producing RNA foci and DPRs, would be protective. However, it is unclear whether reduction of variant 2 would be beneficial. This is the most highly expressed variant, so it is likely to be the main contributor to the functional pool of C9orf72 protein.
Cryo-electron tomography
A high-resolution technique that involves collecting a series of tilted images of frozen hydrated samples using an electron microscope to produce a 3D reconstruction of the sample.
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Bacterial artificial chromosome transgenic mouse models. Bacterial artificial chromosome (BAC) transgenic mice have the advantage of expressing the human C9orf72 gene, with surrounding regulatory regions and flanking sequences, at more physiological levels. Three BAC transgenic models have produced similar findings. Two of these models used BAC constructs 82, 131 containing exons 1-5 of the gene and 300-500 repeats (TABle 2) . The third BAC model expressed the full gene and protein with 100-1000 repeats 132 . All three models developed RNA foci and DPRs in the CNS, but none demonstrated TDP-43 inclusion pathology, neuronal loss or reduced survival. One model developed memory impairment and loss of hippocampal neurons, with an increase in levels of phospho-TDP-43, but was not fully reflective of ALS or FTD 82 . In this model, a single injection of an ASO targeting C9orf72 RNA led to sustained reductions in RNA foci and DPR pathology and improved cognition. Repeat length had a strong influence on the formation of RNA foci, with 100-repeat mice developing no foci and 400-repeat mice developing many foci, despite considerably higher transgene expression in the 100-repeat mice 82 . 
Bacterial artificial chromosome

NATuRE REvIEwS | NEuROLOgy
Only one study has reported BAC transgenic mice with a striking neurodegenerative phenotype 133 . The mice expressed the full gene and different repeat lengths in different lines. Three independent lines, two with ~500 repeats and one with high expression levels of 36 repeats, developed RNA foci, DPR aggregates, TDP-43 pathology and neurodegeneration. A subset of female mice developed an acute motor phenotype, with paralysis, weight loss and decreased survival. The other female and male mice showed slower progressive neurodegeneration. Antisense transcripts and foci were observed at especially high levels in some CNS regions that showed neurodegeneration, whereas sense foci were more evenly distributed. These data show that high expression of short repeats can be toxic, indicating that large repeats are not the critical factor for toxicity in this mouse model. The reasons why female mice are particularly susceptible and why only a subset develops acute disease are currently unclear, although factors such as methylation might be important.
In-depth molecular and phenotypic comparisons between all the BAC models should further our understanding of C9orf72-associated pathogenic mechanisms. One model that expresses the full-length human gene with the repeat expansion recapitulates disease 133 , whereas the other does not 132 . These mice feature different genetic backgrounds and flanking C9orf72 sequences (TABle 2) , which might be contributory factors. Backcrossing the models that did not show a phenotype into different genetic backgrounds, so as to determine whether certain backgrounds facilitate disease, would provide new insight.
Downstream mechanisms
A range of downstream mechanisms in C9FTD/ ALS have been validated across multiple human and non-human model systems and different laboratories (Supplementary Table 1 ). Dysfunctional nucleocytoplasmic transport (NCT) is a prominent mechanism that has been identified in genome-wide screens in yeast 125 and Drosophila 102, 117, 118 and in CRISPR-Cas9 screens in human cells and primary neurons 134 (reviewed elsewhere 97, 135 ). Poly-PR and poly-GR have been shown to interact with proteins that contain low-complexity domains (LCDs), which include many RBPs 116, 136 . LCD proteins can undergo liquid-liquid phase separation (LLPS) to form droplets. Through this process, the proteins become compartmentalized in the cell, forming membraneless organelles, such as nucleoli and stress granules. These organelles facilitate the assembly of RNA and RBPs into ribonucleoproteins and also aid subsequent RNA metabolism. Furthermore, these LCDs can form reversible hydrogels, which have the propensity to fibrillize into irreversible hydrogel-like structures. Mutations frequently occur in the LCDs in several RBPs that are involved in ALS, including FUS and TDP-43 (ReF. 137 ). These mutations can alter the LLPS dynamics of RBPs, leading to their fibrillization and aggregation [138] [139] [140] . Poly-GR and poly-PR interact with LCD proteins in nucleoli and stress granules, thereby impairing LLPS, disrupting the dynamics of assembly of these organelles and affecting mRNA translation and NCT 116, 141, 142 . Aliphatic alcohols, which disrupt phase separation and hydrogel formation, can reduce the interactions between poly-PR and LCD proteins 136 and disrupt the nucleolar localization of poly-PR and poly-GR 116 . Knockdown of several of the LCD proteins modifies the eye degeneration phenotype in a Drosophila poly-GR model 116 . Poly-PR also interacts with LCDs in intermediate filament proteins 136 . Interestingly, arginine-rich DPRs at high concentrations can undergo LLPS 141 . In addition, GGGGCC repeat RNA can undergo gel transition 143, 144 and induce phase transition of RNA granule proteins 143 in the absence of other LCD proteins. These data further implicate altered LLPS in C9FTD/ALS pathogenesis.
Effects on membrane-less organelles have been observed in several other studies. Primary cortical neurons that overexpress poly-PR, leading to the formation of nuclear poly-PR aggregates, show a reduction in cytoplasmic P-bodies and an increase in stress granule formation 42 . However, in cultured cells treated with arsenite, a stress granule inducer, overexpression of poly-PR and poly-GR reduced stress granule formation, whereas poly-GA, poly-GP and poly-PA induced stress granule formation 111 . Poly-PR interacts with translation initiation and elongation factors, and overexpression of poly-GR and poly-PR, but not poly-GA, inhibited translation in vitro and in cell lines 112 . Translational inhibition was attributed to direct binding of poly-GR and poly-PR to mRNA, thereby blocking access to the translation machinery 112 . A second study also observed translational inhibition when (GGGGCC) 31 was expressed in cell lines 145 . This inhibition was accompanied by an increase in stress granule formation (a marker of translational arrest) and A number of RBPs have been shown to interact with C9orf72 repeat RNA in human tissue 12, 61, 107, 173, [183] [184] [185] [186] [187] , in vitro assays 61, 91, 107, 173, 184, 187 , cell models 61, 107, 145, 183, 184, [187] [188] [189] , induced pluripotent stem cell-derived neurons 12, 61, 157 and in vivo models 53, 107, 145, 183 . The most frequently identified RBPs that interact with C9orf72 repeat RNA are the heterogeneous nuclear ribonucleoproteins (hnRNPs), in particular, hnRNP H, although hnRNP A1 and hnRNP A3 are also detected. other RBPs include THo complex subunit 4 (AlYREF), serine/arginine-rich splicing factor 1 (SRSF1), double-stranded RNAspecific editase B2 (ADARB2), nucleolin, Pur-α, Zfp106 and SRSF2. These RBPs are not found consistently across different studies, possibly reflecting the diversity of models and methodologies. However, several of these proteins have been identified in multiple independent studies, indicating that specific RBPs can be sequestered by GGGGCC repeat RNA. only a small subset of RNA foci seem to colocalize with RBPs in human tissue 184 and cells 53, 145 , indicating that sequestration of these proteins is a dynamic process or that diffuse C9orf72 repeat RNA that is not contained within foci can sequester RBPs.
overexpression of Pur-α, an RBP that is involved in transcription regulation 190, 191 , mRNA localization 192, 193 and stress granule formation 194 and was shown to interact with C9orf72 repeat RNA 107, 145 , can ameliorate neurodegeneration in C9orf72 repeatexpressing Drosophila, zebrafish and neuronal cell lines 107, 108 . overexpression of Zfp106 also suppresses toxicity in C9orf72 repeat Drosophila
195
. To date, direct evidence regarding the effects of RBP sequestration in tissue from patients with C9orf72-associated frontotemporal dementia and/or amyotrophic lateral sclerosis is limited, although some hnRNP H targets are altered 187, 196 . A crucial next step is to establish how the implicated RBPs and their targets are mechanistically linked to pathogenesis.
P-bodies
Processing bodies, or P-bodies, are membrane-less organelles within the cytoplasm that are involved in translational repression of mRNAs and in mRNA silencing and degradation. . GGGGCC repeat-induced stress granule formation was also observed in subsequent studies 143, 146 . The translational inhibition might be explained by sequestration of PABPc by GGGGCC repeat RNA but could also be due to the DPR-mediated mechanisms described above.
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A study published in 2018 showed that poly-GR and poly-PR induced stress granule assembly and localization of NCT factors into these stress granules, thereby mediating NCT dysfunction 142 . Inhibition of stress granule assembly abrogated NCT dysfunction and neurodegeneration in patient-derived neurons and in vivo 142 . Altered stress granules and translation inhibition have been implicated in FTD and ALS associated with TDP-43 and FUS inclusions 147 , and they provide an interesting potential common theme across the disease spectrum.
In three elegant studies, GGGGCC repeat overexpression constructs were used to investigate the mechanisms underlying RAN translation. Two of these studies showed that the integrated stress response, via eukaryotic translation initiation factor 2 subunit-α (eIF2α) phosphorylation, selectively increased RAN translation 146, 148 . Therefore, repeat-induced cellular stress could lead to both impaired translation and enhanced RAN translation, causing a negative feedback loop. In addition, two of the studies showed that RAN translation occurred on unspliced, capped mRNA (in which the repeatcontaining intron is retained) and was initiated by an upstream CUG acting as a start codon 146, 149 . By contrast, the third study found that RAN translation occurred on the spliced intronic RNA and was cap-independent, although cap-dependent RAN translation was more efficient 148 . These mechanisms now need to be investigated in the context of endogenous RAN translation.
When applied exogenously to astrocyte cultures, poly-GR and poly-PR 20mers accumulate in the nucleolus, leading to splicing changes and impaired ribosomal RNA (rRNA) maturation 126 . This finding led to the suggestion that these DPRs bind to and impair nuclear RBP complexes that are involved in mRNA splicing, which could in turn affect ribosome biogenesis and other important genes 126 . Interestingly, given the effects of poly-PR and poly-GR on NCT, splicing of Ran GTPase-activating protein (RanGAP), an essential regulator of NCT, was altered 126 . Poly-PR and poly-GR also colocalize with nucleoli in cultured cells, primary neurons, iPSC-derived neurons and Drosophila, leading to abnormal nucleolar morphology 36, 42, 111, 150, 151 . Importantly, the brains of individuals with C9orf79-associated FTLD exhibit bidirectional nucleolar volume changes, with smaller neuronal nucleoli overall but enlarged nucleoli in neurons containing poly-GR inclusions 150 . Other interactome studies suggest that poly-PR and poly-GR associate with the spliceosome component U2 small nuclear ribonucleoprotein (U2 snRNP) in cell nuclear extracts, block spliceosome assembly and disrupt splicing when applied to cell nuclear extracts 152 . These proteins also interact with mitochondrial ribosomal proteins and other ribosomal proteins 153 , and evidence of impaired mitochondrial function has been observed in iPSC-derived neurons from patients with C9FTD/ALS 153, 154 . Ribosomal proteins, heterogeneous nuclear ribonuclear proteins (hnRNPs), nucleolar proteins and RBPs associated with RNA granules have been shown to interact with poly-GR, and overexpression of poly-GR and poly-PR led to decreased levels of rRNA in human cell lines 111 . In agreement with these data, poly-PR was shown to interact with proteins involved in mRNA splicing and ribosome assembly, and with ribosomal proteins 112 . Three studies have shown that in addition to effects on RNA, C9orf72 repeats can induce DNA damage, probably mediated by DPRs 153, 155, 156 . Overall, many cellular pathways have been implicated in gain-of-function toxicity, with the majority of studies focused on poly-GR and poly-PR. Given the highly toxic nature of these DPRs, they are likely to influence multiple pathways. Links between the downstream mechanisms and specific DPRs or repeat RNA have not yet been established, and sensitive techniques to measure both repeat RNA and DPRs in models expressing pure GGGGCC repeats will be required to enable the effects of individual molecular species to be distinguished.
Another important issue that remains to be addressed is whether different DPRs or repeat RNA and DPRs act synergistically, potentially in conjunction with loss of function of C9orf72, to elicit downstream effects. Crossing of models that express different DPR species should help to address this question. A further priority is to develop physiologically relevant models to reflect endogenous levels of C9orf72 repeat RNA and DPRs, and human iPSC-derived neuronal models will be a key tool in this regard. Furthermore, C9orf72 protein depletion, repeat RNA and DPRs might have non-cell-autonomous effects, and iPSC models of neuronal, glial and muscle co-culture should increase our understanding of these complex interactions.
Therapeutic strategies
Targeting C9orf72 RNA or DNA ASOs that target C9orf72 RNA can rescue C9orf72-specific pathologies 12, 13, 46, 157 , downstream gene expression changes 12, 157 , NCT defects 102 and TDP-43 mislocalization 102 in C9orf72 fibroblasts or iPSC-derived neurons. These ASOs also reduce NCT defects and neurodegeneration in Drosophila 102 and diminish sense RNA foci and DPRs in mice 46, 82 . ASO trials in humans are planned, and the feasibility of this strategy has a precedent in studies of superoxide dismutase 1 (SOD1)-targeting ASOs in patients with ALS 158 . An alternative strategy is to use compounds that target the secondary structure of C9orf72 repeat RNA 45, 102, [159] [160] [161] . These compounds could prevent sequestration of RBPs and/or interfere with the RNA structure to prevent RAN translation. Such molecules have been shown to affect the secondary structure of C9orf72 repeat RNA in vitro 45, 159, 161 , to reduce the production of RNA foci and DPRs when applied to patient neurons 45, 160 and Drosophila 160 and to rescue nuclear import defects and neurodegeneration in a Drosophila model 102 . Targeting of the transcription elongation factor SPT4 reduces levels of sense and antisense C9orf72 repeat www.nature.com/nrneurol transcripts and ameliorates disease phenotypes in vitro and in vivo, including in C9orf72 iPSC-derived neurons 162 . Single-stranded small inhibitory RNAs have also been proposed as a strategy to silence the C9orf72 repeat RNA 163 . In addition, two studies have shown that the use of the CRISPR-Cas9 system to target either GGGGCC repeat DNA 164 -thus reducing repeat transcription -or repeat RNA 165 can reduce RNA foci and DPR levels in cell lines. On the basis of these studies, targeting of C9orf72 RNA or DNA is a promising strategy, and ASOs are currently the most advanced in terms of clinical development.
Targeting DPRs and TDP-43
In other neurodegenerative diseases, active and passive immunological approaches have been used to target toxic proteins, such as amyloid-β 166 , tau 167, 168 and α-synuclein 169, 170 , leading to improved pathology and phenotypes in model systems. With the ongoing development of specific DPR antibodies, passive immunization to the DPRs could present a novel therapeutic approach for C9FTD/ALS, and poly-GA-specific antibodies have been shown to reduce intracellular poly-GA aggregation and seeding activity of C9FTD/ALS brain extracts 171 . In addition, given that C9FTD/ALS pathogenesis converges on TDP-43, anti-TDP-43 immunotherapy could be a compelling strategy if the pathogenic species can be specfically targeted.
Current strategies in other neurodegenerative diseases are based on targeting of the extracellular pool of protein, which is presumably involved in cell-to-cell transmission. The success of such an approach in the case of DPRs and TDP-43 would depend on whether there is a disease-relevant extracellular pool to target. If not, methods to deploy antibodies intracellularly would be required. Other important factors to consider are the ideal timing of these treatments, which DPRs and conformations to target, the specificity and safety of the treatment and the risks of precipitating an autoimmune response. As short repetitive sequences similar to DPRs are present across the proteome, specificity might present a barrier. Increasing clearance of DPRs by other mechanisms could also be effective; for example, the small heat shock protein HSPB8 was shown to reduce DPR levels, probably via the autophagy pathway 172 .
Targeting downstream mechanisms
Targeting of downstream mechanisms might represent a useful therapeutic strategy for C9FTD/ALS. Reducing nuclear export by targeting the nuclear export factors serine/arginine-rich splicing factor 1 (SRSF1) or exportin 1 ameliorates toxicity in C9orf72-repeat Drosophila 102, 173 , possibly by reducing the levels of cytoplasmic repeat RNA (and, thus, DPRs) or through a more general mechanism to reverse alterations in NCT. Importantly, in addition to the proof-of-concept genetic knockdown approaches that were used to reduce SRSF1 and exportin 1, small-molecule exportin 1 inhibitors were used, indicating a potential route to the clinic. An important issue to address is whether the therapeutic window is sufficiently large when targeting nuclear export, which is a fundamental cellular process.
Inhibition of stress granule formation, using either ASOs targeting ataxin 2 or small molecules, prevents NCT defects in iPSC-derived neurons from patients with C9orf72-associated ALS and neurodegeneration in a C9orf72 repeat fly model 142 . As ASOs targeting ataxin 2 have shown success in extending the lifespan of an ALS mouse model overexpressing TDP-43 (ReF.
174
), this strategy and its underlying mechanisms are of clear interest.
An SRC-ABL pathway inhibitor that augments autophagy improved the survival of iPSC-derived neurons from patients with ALS, including those with C9FTD/ ALS, suggesting that this approach could be beneficial for several forms of FTD and ALS 78 . Knockdown of thioredoxin-related transmembrane protein 2 (TMX2), an endoplasmic reticulum protein that was identified in CRISPR-Cas9 screens in human cells and primary neurons overexpressing poly-PR, modulated endoplasmic reticulum stress and increased survival of neurons derived from patients with C9orf72-associated ALS 134 . Whether TMX2 is druggable awaits further study.
High-throughput drug screens -for example, using iPSC-derived neuronal models 54, 78, 175 -will be of great importance in establishing treatments to reduce levels of repeat RNA and DPRs, repair dysfunctional cellular mechanisms and rescue disease phenotypes.
Conclusions
Our knowledge of C9FTD/ALS has increased exponentially within a relatively short time period. Dissection of the disease mechanisms has not been straightforward, and the emerging picture is one of a combination of diverse factors that lead to neurodegeneration. Given the relative importance of C9orf72 repeat expansions as a causative factor for ALS and FTD, rapid translation of the accumulated knowledge into therapeutic strategies would have a substantial impact on patients with these devastating neurodegenerative diseases. 
